Natus Medical Announces Fourth Quarter and Full Year 2019 Financial Results

• Fourth quarter revenue of $131.8 million
• Fourth quarter GAAP earnings per diluted share of $0.10
• Fourth quarter non-GAAP earnings per diluted share of $0.46
• Provides annual revenue and earnings guidance for 2020

PLEASANTON, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three months and full year ended December 31, 2019.

Key Results During the Quarter

• GAAP gross profit margins increased 440 basis points during the fourth quarter year over year
• GAAP and Non-GAAP EPS increased $0.45 and $0.03, respectively
• Reduced inventory by $8.5 million during the fourth quarter
• Generated $12.7 million in operating cash flow
• Reduced debt by $15.0 million, with net cash exceeding net debt

For the fourth quarter ended December 31, 2019, the Company reported revenue of $131.8 million, a decrease of 6.5% compared to $141.0 million reported for the fourth quarter 2018. GAAP gross profit margin was 61.3% during the fourth quarter of 2019 compared to 56.9% in the fourth quarter 2018. GAAP net income was $3.2 million, or $0.10 per diluted share, compared with GAAP net loss of $11.6 million, or $0.35 per share in the fourth quarter 2018.

Non-GAAP earnings per diluted share was $0.46 for the fourth quarter 2019, compared to $0.43 in the fourth quarter 2018. Non-GAAP net income was $15.4 million for the fourth quarter 2019 compared to $14.5 million in the fourth quarter 2018. Non-GAAP gross profit margin was 62.1% in the fourth quarter 2019 compared to 58.2% reported for the fourth quarter of 2018.

For the full year ended December 31, 2019, the Company reported revenue of $495.5 million, a decrease of 6.7% compared to $530.9 million reported for the same period in 2018. GAAP gross profit margin was 59.0% vs. 57.3% reported for the same period in 2018. GAAP net loss was $14.1 million, or $0.42 per share, compared with GAAP net loss of $22.9 million, or $0.69 per share in the same period in 2018.

Non-GAAP earnings per diluted share was $1.24 for the full year ended December 31, 2019, compared to $1.42 in the same period in 2018. The Company reported non-GAAP net income of $42.0 million for the year ended December 31, 2019, compared to the prior year's non-GAAP net income of $47.5 million.

“Our Neuro business showed significant growth during the quarter with a 14.5% increase in year over year after adjusting for the divestiture of GND, driven by new cybersecurity features and Windows 10 upgrades in our EEG products as well as strength in our sleep and neurosurgery business. Overall, we achieved organic revenue growth of 1% after adjusting for our divestitures. Our non-GAAP gross profit margins improved 390 basis points during the quarter. Strong operating cash flows of $12.7 million and another $15 million in debt reduction put Natus in a net cash position at the end of the year,” said Jonathan Kennedy, President and Chief Executive Officer of Natus. “Both the Newborn Care and the Hearing & Balance businesses declined during the quarter. However, we expect them to return to growth in the first quarter of 2020 as we return key products to the market.”

“2019 was a year of major transformation and accomplishment for Natus,” continued Mr. Kennedy. “We completed our ‘One Natus’ restructuring project, exited five non-core businesses and, focused on the execution of our central nervous and sensory systems strategy. We simplified our supply chain, consolidating multiple distribution centers and two of our manufacturing locations. We also executed a strategic agreement with industry leader Pediatrix Medical Group to supply our best-in-class ALGO newborn hearing screeners and supplies to their 500 hospitals.”

“With most of our restructuring complete, we can now focus on the execution of our strategic plan and growing our business,” concluded Mr. Kennedy.

Financial Guidance

For the first quarter of 2020, the Company's revenue is expected to be between $113.0 million and $117.0 million and non-GAAP earnings per share is expected to be between $0.19 and $0.25.

For the full year 2020, the Company's revenue is expected to be between $480.0 million and $490.0 million and non-GAAP expected earnings per share to be between $1.45 and $1.55.

The Company's non-GAAP earnings per share guidance excludes charges of approximately $4.6 million and $19.1 million for amortization expense associated with intangible assets from prior acquisitions, certain other expenses, and related tax effects for the first quarter 2020 and full year, respectively, which the Company anticipates will reduce GAAP earnings per share by approximately $0.13 and $0.56 for the respective periods.

Use of Non-GAAP Financial Measures

The Company presents in this release its non-GAAP net income, non-GAAP earnings per share, non-GAAP gross margin and non-GAAP operating margin results which exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, certain discrete items, direct costs of acquisitions, and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included in this press release.

The Company believes that the presentation of results excluding these charges or gains provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results and better reflects the ongoing economics of the Company's operations. The Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.

Specifically, the Company excludes the following charges, gains, and their related tax effects in the calculation of non-GAAP net income, non-GAAP earnings per share and non-GAAP operating expense: 1) Non-cash amortization expense associated with certain acquisition-related intangibles. The charges reflect an estimate of the cost of acquired intangible assets over their estimated useful lives. 2) Restructuring and other non-recurring charges. The Company has over time completed multiple acquisitions of other companies and businesses. Following an acquisition the Company will, as it determines appropriate, initiate restructuring events to eliminate redundant costs. Restructuring expenses, which are excluded in the non-GAAP items, are exclusively related to permanent reductions in our workforce and redundant facility closures. Other non-recurring costs are associated with the transition of the executive management team. These costs can include stock compensation from accelerated vesting of stock, severance payouts and related payroll expenses.  3) Certain discrete items. These items represent significant infrequent charges or gains that management believes should be viewed outside of normal operating results, and each significant discrete transaction is evaluated to determine whether it should be excluded from non-GAAP reporting. These items are specifically identified when they occur. 4) Direct costs of acquisitions.  These are direct acquisition-related costs that occur when the Company makes an acquisition, such as professional fees, due diligence costs, and earn-out adjustments.

The Company applies GAAP methodologies in computing its non-GAAP tax provision by determining the annual expected effective tax rate after taking into account items excluded for non-GAAP financial reporting purposes.  The Company’s non-GAAP tax expense and its non-GAAP effective tax rate are generally higher than its GAAP tax expense and GAAP effective tax rate because the income subject to taxes would be higher due to the effect of the expenses excluded from non-GAAP financial reporting. The nature of each quarterly discrete transaction will be evaluated to determine whether it should be excluded from non-GAAP reporting.

The Company's management uses these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods and the Company believes that investors also benefit from being able to refer to these non-GAAP financial measures along with the GAAP operating results. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.

Conference Call

Natus has scheduled a conference call to discuss this announcement beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) today, February 6, 2020. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 1227558. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 1227558. The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company’s Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical can be found at www.natus.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. These forward-looking statements include, without limitation, statements regarding the Company's ability to achieve improvements in operational efficiency and to execute its strategic plans and the anticipated performance and product offerings of the Company's business units. These statements relate to current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. The Company's future results could differ materially due to a number of factors, including the ability of the Company to realize the anticipated benefits from its new structure or from its consolidation strategy, effects of competition, the Company's ability to successfully integrate and achieve its profitability goals from recent acquisitions, the demand for Natus products and services, the impact of adverse global economic conditions and changing governmental regulations, including foreign exchange rate changes, on the Company's target markets, the Company's ability to expand its sales in international markets, the Company's ability to maintain current sales levels in a mature domestic market, the Company's ability to control costs, risks associated with bringing new products to market, and the Company's ability to fulfill product orders on a timely basis, as well as those factors identified under the heading Item 1A “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Natus disclaims any obligation to update information contained in any forward looking statement, except as required by law.

Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
[phone]
[e-mail]

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited)
(in thousands, except per share amounts)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Revenue	$	131,756			$	140,991			$	495,515			$	530,891
Cost of revenue	49,251				58,103				196,491				217,952
Intangibles amortization	1,679				2,689				6,916				8,924
Gross profit	80,826				80,199				292,108				304,015
Gross profit margin	61.3		%		56.9		%		59.0		%		57.3		%
Operating expenses:
Marketing and selling	31,696				34,206				128,509				136,680
Research and development	18,354				15,296				58,295				61,482
General and administrative	15,310				13,632				59,419				70,599
Intangibles amortization	3,844				9,151				15,144				22,585
Restructuring	3,592				23,049				44,739				37,231
Total operating expenses	72,796				95,334				306,106				328,577
Income (loss) from operations	8,030				(15,135		)		(13,998		)		(24,562		)
Interest expense	(878		)		(1,545		)		(4,937		)		(6,785		)
Other income (expense)	105				(1,209		)		(757		)		(913		)
Income (loss) before tax	7,257				(17,889		)		(19,692		)		(32,260		)
Provision for income tax expense (benefit)	4,018				(6,256		)		(5,579		)		(9,325		)
Net income (loss)	$	3,239			$	(11,633	)		$	(14,113	)		$	(22,935	)
Earnings (loss) per share:
Basic	$	0.10			$	(0.35	)		$	(0.42	)		$	(0.69	)
Diluted	$	0.10			$	(0.35	)		$	(0.42	)		$	(0.69	)
Weighted-average shares:
Basic	33,691				33,495				33,696				33,111
Diluted	33,829				33,495				33,696				33,111

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands)
	December 31,				September 30,				December 31,
	2019				2019				2018
ASSETS
Current assets:
Cash and investments	$	63,297			$	63,062			$	56,373
Accounts receivable	115,226				108,964				127,041
Inventories	71,215				75,107				79,736
Other current assets	19,204				27,735				22,625
Total current assets	268,942				274,868				285,775
Property and equipment	24,702				25,095				22,913
Operating lease right-of-use assets	15,046				16,059				—
Goodwill and intangible assets	262,116				265,152				287,097
Deferred income tax	31,006				21,955				22,639
Other assets	21,509				25,984				19,716
Total assets	$	623,321			$	629,113			$	638,140
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	27,065			$	30,096			$	28,805
Current portion of long-term debt	35,000				35,000				35,000
Accrued liabilities	53,851				56,657				52,568
Deferred revenue	20,246				19,242				17,073
Current portion of operating lease liabilities	5,871				5,901				—
Liabilities and accrued impairment held for sale	—				—				—
Total current liabilities	142,033				146,896				133,446
Long-term liabilities:
Long-term debt	19,665				34,618				69,474
Deferred income tax	14,249				8,129				16,931
Operating lease liabilities	12,051				13,112				—
Other long-term liabilities	17,644				20,200				19,845
Total liabilities	205,642				222,955				239,696
Total stockholders’ equity	417,679				406,158				398,444
Total liabilities and stockholders’ equity	$	623,321			$	629,113			$	638,140

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(in thousands)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Operating activities:
Net income (loss)	$	3,239			$	(11,633	)		$	(14,113	)		$	(22,935	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Provision for losses on accounts receivable	409				1,038				1,903				6,909
Depreciation and amortization	7,308				8,211				30,254				33,863
Goodwill impairment	—				14,846				—				14,846
(Gain) loss on disposal of property and equipment	(33		)		336				449				746
Warranty reserve	298				2,095				2,886				2,168
Share-based compensation	1,975				1,605				8,352				17,051
Impairment of intangible assets	—				8,192				—				8,192
Impairment charge for sale of entity	—				—				24,571				—
Changes in operating assets and liabilities:
Accounts receivable	(7,137		)		(8,154		)		10,153				(5,199		)
Inventories	9,412				(2,260		)		7,338				(7,443		)
Prepaid expenses and other assets	8,749				9,280				(1,894		)		(5,118		)
Accounts payable	(3,162		)		7,904				(1,555		)		4,105
Accrued liabilities	(6,134		)		(3,495		)		(5,061		)		(2,527		)
Deferred revenue	1,021				331				3,392				2,076
Deferred income tax	(3,198		)		(14,231		)		(6,015		)		(13,714		)
Net cash provided by operating activities	12,747				14,065				60,660				33,020
Investing activities:
Acquisition of businesses, net of cash acquired	—				—				—				151
Purchases of property and equipment	(986		)		(2,748		)		(4,858		)		(7,875		)
Purchase of intangible assets	—				(28		)		(13		)		(665		)
Net cash used in investing activities	(986		)		(2,776		)		(4,871		)		(8,389		)
Financing activities:
Proceeds from stock option exercises and ESPP	1,441				933				3,634				11,448
Repurchase of common stock	—				—				—				(5,630		)
Taxes paid related to settlement of equity awards	(93		)		(10		)		(1,689		)		(5,183		)
Principal payments of financing lease liability	(198		)		—				(602		)		—
Contingent consideration earn-out	—				—				—				(147		)
Payments on borrowings	(15,000		)		(10,000		)		(50,000		)		(50,000		)
Net cash used in financing activities	(13,850		)		(9,077		)		(48,657		)		(49,512		)
Exchange rate changes effect on cash and cash equivalents	2,324				(279		)		(208		)		(7,696		)
Net decrease in cash and cash equivalents	235				1,933				6,924				(32,577		)
Cash and cash equivalents, beginning of period	63,062				54,440				56,373				88,950
Cash and cash equivalents, end of period	$	63,297			$	56,373			$	63,297			$	56,373

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
GAAP based results:
Income (loss) before provision for income tax	$	7,257			$	(17,889	)		$	(19,692	)		$	(32,260	)
Non-GAAP adjustments:
Intangibles amortization (COGS)	1,679				2,689				6,916				8,924
Recall accrual and remediation efforts (COGS)	(492		)		163				(425		)		1,538
Restructuring and other non-recurring costs (COGS)	—				(548		)		989				326
Direct costs of acquisitions (COGS)	(153		)		(439		)		887				3,443
Intangibles amortization (OPEX)	3,844				9,151				15,145				22,591
Recall accrual and remediation efforts (R&D)	—				1,328				—				6,203
Restructuring and other non-recurring costs (OPEX)	6,759				23,156				20,653				41,476
Restructuring and other non-recurring costs (OI&E)	—				—				28,218				366
Direct costs of acquisitions (OPEX)	285				273				1,241				4,399
Extraordinary annual meeting expenses	—				—				—				2,230
Litigation (OPEX)	185				310				887				1,306
Non-GAAP income before provision for income tax	19,364				18,194				54,819				60,542
Income tax expense, as adjusted	$	3,923			$	3,692			$	12,846			$	13,049
Non-GAAP net income	$	15,441			$	14,502			$	41,973			$	47,493
Non-GAAP earnings per share:
Basic	$	0.46			$	0.43			$	1.25			$	1.43
Diluted	$	0.46			$	0.43			$	1.24			$	1.42
Weighted-average shares used to compute
Basic non-GAAP earnings per share	33,691				33,495				33,696				33,111
Diluted non-GAAP earnings per share	33,829				33,658				33,800				33,455

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
GAAP Gross Profit	$	80,826			$	80,199			$	292,108			$	304,015
Amortization of intangibles	1,679				2,689				6,916				8,924
Direct cost of acquisitions	(153		)		(439		)		887				3,443
Recall accrual and remediation efforts	(492		)		163				(425		)		1,538
Restructuring and other non-recurring costs	—				(548		)		989				326
Non-GAAP Gross Profit	$	81,860			$	82,064			$	300,475			$	318,246
Non-GAAP Gross Margin	62.1		%		58.2		%		60.6		%		59.9		%
GAAP Operating Income (Loss)	$	8,030			$	(15,135	)		$	(13,998	)		$	(24,562	)
Amortization of intangibles	5,523				11,840				22,061				31,515
Recall accrual and remediation efforts	(492		)		1,491				(425		)		7,741
Litigation	185				310				887				1,306
Restructuring and other non-recurring costs	6,759				22,608				49,860				41,802
Direct cost of acquisitions	132				(166		)		2,128				7,842
Extraordinary annual meeting expenses	—				—				—				2,230
Non-GAAP Operating Profit	$	20,137			$	20,948			$	60,513			$	67,874
Non-GAAP Operating Margin	15.3		%		14.9		%		12.2		%		12.8		%
GAAP Income Tax Benefit (Expense)	$	4,018			$	(6,256	)		$	(5,579	)		$	(9,325	)
Effect of accumulated change of pretax income	407				24,704				9,254				20,003
Effect of change in annual expected tax rate	(558		)		(16,719		)		(2,298		)		(2,599		)
Repatriation tax adjustment	—				2,576				(177		)		2,676
Stock-based compensation adjustment	—				79				—				1,701
Valuation allowance for GAAP purposes	—				(15		)		—				1,270
Restructuring and other expenses	56				(677		)		11,646				(677		)
Non-GAAP Income Tax Expense	$	3,923			$	3,692			$	12,846			$	13,049
	Three Months Ended				Year Ended
	March 31, 2020				December 31, 2020
GAAP EPS Guidance		$0.06 - $0.12				$0.89 - $0.99
Amortization of intangibles		0.16				0.64
Restructuring and other non-recurring costs		0.01				0.02
Tax effect		(0.04)				(0.10)
Non-GAAP EPS Guidance		$0.19 - $0.25				$1.45 - $1.55

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GROSS PROFIT MARGIN BY END MARKETS (unaudited)
(in thousands)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Neuro:
Revenue	$	80,879			$	73,664			$	287,058			$	279,787
Cost of revenue	28,471				28,273				104,281				107,845
Intangibles amortization	883				980				3,702				4,487
Gross profit	$	51,525			$	44,411			$	179,075			$	167,455
Gross profit margin	63.7		%		60.3		%		62.4		%		59.9		%
Newborn care:
Revenue	$	27,807			$	35,174			$	110,912			$	133,872
Cost of revenue	10,016				13,634				45,197				57,054
Intangibles amortization	64				953				257				1,311
Gross profit	$	17,727			$	20,587			$	65,458			$	75,507
Gross profit margin	63.8		%		58.5		%		59.0		%		56.4		%
Hearing & balance:
Revenue	$	23,070			$	32,153			$	97,545			$	117,232
Cost of revenue	10,764				16,196				47,013				53,053
Intangibles amortization	732				756				2,957				3,126
Gross profit	$	11,574			$	15,201			$	47,575			$	61,053
Gross profit margin	50.2		%		47.3		%		48.8		%		52.1		%
Consolidated:
Revenue	$	131,756			$	140,991			$	495,515			$	530,891
Cost of revenue	49,251				58,103				196,491				217,952
Intangibles amortization	1,679				2,689				6,916				8,924
Gross profit	$	80,826			$	80,199			$	292,108			$	304,015
Gross profit margin	61.3		%		56.9		%		59.0		%		57.3		%

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP GROSS MARGIN BY END MARKETS (unaudited)
(in thousands)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Neuro:
GAAP Gross Profit	$	51,525			$	44,411			$	179,075			$	167,455
Amortization of intangibles	883				980				3,702				4,487
Acquisition charges	(153		)		(449		)		887				3,383
Recall accrual and remediation efforts	(67		)		—				(67		)		—
Restructuring and other non-recurring costs	—				159				—				159
Non-GAAP Gross Profit	$	52,188			$	45,101			$	183,597			$	175,484
Non-GAAP Gross Margin	64.5		%		61.2		%		64.0		%		62.7		%
Newborn care:
GAAP Gross Profit	$	17,727			$	20,587			$	65,458			$	75,507
Amortization of intangibles	64				953				257				1,311
Recall accrual and remediation efforts	(425		)		163				(996		)		1,538
Restructuring and other non-recurring costs	—				(731		)		814				118
Non-GAAP Gross Profit	$	17,366			$	20,972			$	65,533			$	78,474
Non-GAAP Gross Margin	62.5		%		59.6		%		59.1		%		58.6		%
Hearing & balance:
GAAP Gross Profit	$	11,574			$	15,201			$	47,575			$	61,053
Amortization of intangibles	732				756				2,957				3,126
Acquisition charges	—				10				—				60
Recall accrual and remediation efforts	—				—				638				—
Restructuring and other non-recurring costs	—				24				175				49
Non-GAAP Gross Profit	$	12,306			$	15,991			$	51,345			$	64,288
Non-GAAP Gross Margin	53.3		%		49.7		%		52.6		%		54.8		%
Consolidated:
GAAP Gross Profit	$	80,826			$	80,199			$	292,108			$	304,015
Amortization of intangibles	1,679				2,689				6,916				8,924
Acquisition charges	(153		)		(439		)		887				3,443
Recall accrual and remediation efforts	(492		)		163				(425		)		1,538
Restructuring and other non-recurring costs	—				(548		)		989				326
Non-GAAP Gross Profit	$	81,860			$	82,064			$	300,475			$	318,246
Non-GAAP Gross Margin	62.1		%		58.2		%		60.6		%		59.9		%

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
GEOGRAPHIC REVENUE (unaudited)
(in thousands)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Consolidated Revenue:
United States	$	79,166			$	78,725			$	292,221			$	300,860
International	52,590				62,266				203,294				230,031
Totals	$	131,756			$	140,991			$	495,515			$	530,891
United States	60		%		56		%		59		%		57		%
International	40		%		44		%		41		%		43		%
Totals	100		%		100		%		100		%		100		%

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
REVENUE AFTER EXITED PRODUCTS (unaudited)
(in millions)
	Quarter Ended								Year Ended
	December 31, 2019				December 31, 2018				December 31, 2019				December 31, 2018
Revenue	$	131.8			$	141.0			$	495.5			$	530.9
Newborn care*	(0.4		)		(5.3		)		(4.5		)		(20.6		)
Neuro*	(0.1		)		(3.4		)		(1.2		)		(14.3		)
Hearing & balance*	(0.1		)		(1.5		)		(0.1		)		(11.3		)
Revenue after exited products	$	131.2			$	130.8			$	489.7			$	484.7
*Newborn care, Neuro, and Hearing & balance include exited businesses (GND, Neurocom, Medix) and other end of sales products.